Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Editas Medicine

Editas Medicine, Inc. engages in the development and commercialization of genome editing technology. Its technology includes clustered, regularly interspaced short palindromic repeats (CRISPR), and CRISPR associated protein 9 (Cas9). The company was founded by Feng Zhang, Jennifer A. Doudna, George McDonald Church, J. Keith Joung and David R. Liu in September 2013 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Editas Medicine reports positive clinical data and strategic advancements

Editas Medicine's Q4 2022 earnings call highlighted positive clinical data, strong financial positioning, and strategic advancements in genome editing medicines.
While facing challenges in hiring key personnel, regulatory negotiations, and strategic realignment, the company is well-positioned for therapeutic advancements and market growth.
Opportunities lie in replicating clinical success, strategic partnerships, and advancements in pipeline development, supported by strong collaborations and financial prospects.
Overall, Editas Medicine's performance, strengths, challenges, and opportunities reflect a company poised for continued growth and innovation in the genome editing space.

Editas Medicine excels in Q1 with promising trials and regulatory progress

Editas Medicine's Q1 performance was strong, supported by promising clinical trial data and regulatory advancements.
The company's focus on gene editing for hemoglobinopathies and strong IP position are key strengths.
Challenges include differentiation from competitors and legal uncertainties, while opportunities lie in expansion and regulatory progress.
Overall, Editas Medicine is well-positioned for growth in the gene editing market.

Editas Medicine reports positive data, raises funds, and faces challenges

Editas Medicine shows strong performance with positive clinical data and financial raise
Facing challenges in pipeline adjustment and FDA discussions for facility planning
Opportunities lie in expanding trials, partnerships, and enhancing R&D focus

Editas Medicine advances EDIT-301 program, poised for gene therapy leadership

Editas Medicine is making significant progress with EDIT-301, showcasing confidence in their gene editing capabilities and operational readiness.
While facing challenges in safety monitoring and differentiation, the company's strategic hires, strong IP portfolio, and focus on regulatory pathways provide a solid foundation for growth.
With a clear roadmap for clinical data presentation, manufacturing scaling, and regulatory submissions, Editas is well-positioned to capitalize on opportunities in gene editing therapies.

Editas Medicine exceeds enrollment goals and showcases promising clinical data

Editas Medicine's Q4 2023 Earnings Call showcased strong performance in enrollment, clinical data, and financials. The company's strengths lie in its research capabilities, cash position, and progress in key trials. Challenges include addressing analyst queries and optimizing manufacturing processes.

Editas Medicine reports robust Q1 performance and advances in gene editing

Editas Medicine's Q1 2024 performance reflects solid revenue and strong financial reserves, driven by R&D investments in the Renace program.
The company's strengths lie in its financial stability, advancing in vivo capabilities, and fostering strong collaborations for future growth.
Challenges include legal uncertainties, operational optimizations, and strategic complexities in therapeutic development.
Opportunities abound in driving Renace, regulatory progress for Reni-cel, and leveraging innovative in vivo approaches for unique indications.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Editas Medicine, Inc. (NASDAQ:EDIT ) 2024 Cantor Global Healthcare Conference September 17, 2024 1:20 PM ET Company Participants Gilmore O'Neill - CEO Conference Call Participants Eric Schmidt - Cantor Fitzgerald Eric Schmidt Good afternoon, everyone. My name is Eric Schmidt, and I'm one of the, biotechnology analyst at Cantor Fitzgerald.

Editas Medicine, Inc. (EDIT) 2024 Cantor Global Healthcare Conference (Transcript)

Five9

Origin Materials

There has been a noticeable shift in the stock market over the last two months.

Buy These 3 Small-Cap Stocks for 90% to 301% Returns

Editas Medicine, Inc. (NASDAQ:EDIT ) Wells Fargo 2024 Healthcare Conference September 5, 2024 4:30 PM ET Company Participants Gilmore O'Neill - CEO Erick Lucera - CFO Conference Call Participants Yanan Zhu - Wells Fargo Securities Yanan Zhu Let's get started. Thanks, everyone, for being here.

Editas Medicine, Inc. (EDIT) Presents at Wells Fargo 2024 Healthcare Conference (Transcript)

Editas Medicine, Inc. (NASDAQ:EDIT ) Morgan Stanley 22nd Annual Global Healthcare Conference September 4, 2024 4:05 PM ET Company Participants Gilmore O'Neill - President and Chief Executive Officer Erick Lucera - Executive Vice President and Chief Financial Officer Conference Call Participants Terence Flynn - Morgan Stanley Terence Flynn All right. Thanks for joining us everybody.

Editas Medicine, Inc. (EDIT) Presents at Morgan Stanley 22nd Annual Global Healthcare Conference (Transcript)

Editas (EDIT) reports lower-than-expected second-quarter 2024 results as both earnings and revenues miss estimates. The stock falls 12.2%.

Editas (EDIT) Q2 Earnings & Revenues Miss Estimates, Stock Down

Editas Medicine, Inc. (NASDAQ:EDIT ) Q2 2024 Results Conference Call August 7, 2024 8:00 AM ET Company Participants Cristi Barnett - Corporate Communications and Investor Relations Gilmore O'Neill - Chief Executive Officer Baisong Mei - Chief Medical Officer Erick Lucera - Chief Financial Officer Linda Burkly - Chief Scientific Officer Caren Deardorf - Chief Commercial and Strategy Officer Conference Call Participants Jack Allen - Baird Samantha Semenkow - Citi Eric Schmidt - Cantor Fitzgerald Terence Flynn - Morgan Stanley Gena Wang - Barclays Mary Kate Davis - Bank of America Brian Cheng - JPMorgan Dae Gon Ha - Stifel Luca Issi - RBC Capital Phil Nadeau - TD Cowen Yanan Zhu - Wells Fargo Securities Operator Good morning and welcome to the Editas Medicine's Second Quarter 2024 Conference Call. All participants are now in a listen-only mode.

Editas Medicine, Inc. (EDIT) Q2 2024 Earnings Call Transcript

Editas Medicine (EDIT) came out with a quarterly loss of $0.82 per share versus the Zacks Consensus Estimate of a loss of $0.69. This compares to loss of $0.56 per share a year ago.

Editas Medicine (EDIT) Reports Q2 Loss, Misses Revenue Estimates

On track to present additional clinical data from the RUBY trial and the EdiTHAL trial by year-end In vivo preclinical proof-of-concept for an undisclosed indication on-track by year-end Strong financial position with runway into 2026 CAMBRIDGE, Mass., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage gene editing company, today reported financial results for the second quarter 2024 and provided business updates.

Editas Medicine Announces Second Quarter 2024 Results and Business Updates

CAMBRIDGE, Mass., July 31, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage gene editing company, today announced that it will host a conference call and webcast on Wednesday, August 7, 2024, at 8:00 a.m. ET to discuss results for the second quarter 2024 and to provide a corporate update.

Editas Medicine Announces Second Quarter 2024 Results Conference Call and Corporate Update

CRISPR Therapeutics

Intellia Therapeutics

Gene-editing stocks are a promising investment because the field is steadily advancing in the areas of medicine and biotechnology.  Examples include CRISPR and other gene-editing technologies.

3 Gene-Editing Stocks That Could Be Multibaggers in the Making: July Edition

CRISPR technology, or Clustered Regularly Interspaced Short Palindromic Repeats, is a revolutionary gene-editing tool that allows scientists to make precise modifications to the DNA of living organisms. It's one of the hottest trends in the stock market today, so I've made a list of three of the most profitable CRISPR stocks to consider.

3 Profitable CRISPR Stocks Earning Analysts' Praise

Global X Genomics & Biotechnology ETF

Gene editing is revolutionizing medicine, creating substantial opportunities for some of the best gene editing stocks. With the technology, we can fix faulty genes, or replace them with healthier genes in an attempt to cure diseases or help the body fight disease.

The 3 Best Gene Editing Stocks to Buy in July 2024

Gene editing is a game-changer. With it, we can remove cells from your body, edit them, and then reintroduce them back into the body.

Rags to Riches: 3 Gene Editing Stocks That Could Make Early Investors Rich

Gene-editing stocks has been gaining substantial attention, as the industry holds the potential to revolutionize medicine. From curing genetic disorders to enhancing agricultural productivity, the applications are vast and transformative.

3 Gene Editing Stocks That Could Make Your Grandchildren Rich

Editas (EDIT) reports positive new safety and efficacy data from the RUBY and EdiTHAL studies evaluating its investigational gene therapy, reni-cel, for SCD and TDT, respectively.

Editas (EDIT) Reports Upbeat New Data From Reni-Cel Studies

All patients treated in the RUBY trial are free of vaso-occlusive events post- renizgamglogene autogedtemcel (reni-cel) infusion

Editas Medicine Reports New Safety and Efficacy Data from the RUBY Trial of Reni-cel in 18 Patients with Sickle Cell Disease, Presented at the European Hematology Association (EHA) Annual Congress

All patients treated in the EdiTHAL trial maintained hemoglobin levels above the transfusion threshold and are transfusion-free post- renizgamglogene autogedtemcel (reni-cel) infusion

Editas Medicine Announces New Safety and Efficacy Data from the EdiTHAL Trial of Reni-cel in 7 Patients with Transfusion-dependent Beta Thalassemia, Presented at the European Hematology Association (EHA) Annual Congress

Editas Medicine, Inc. (NASDAQ:EDIT ) RBC Capital Markets Global Healthcare Conference Call May 15, 2024 2:05 PM ET Company Participants Gilmore O'Neill - Chief Executive Officer Conference Call Participants Luca Issi - RBC Capital Markets Luca Issi Thanks, everybody. Luca Issi, senior biotech analyst here at RBC Capital Markets.

Editas Medicine, Inc. (EDIT) RBC Capital Markets Global Healthcare Conference (Transcript)

CAMBRIDGE, Mass., May 14, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage gene editing company, today announced that two abstracts, including one oral presentation and one poster presentation, detailing clinical data from the RUBY and EdiTHAL trials of renizgamglogene autogedtemcel (reni-cel) have been accepted for presentation at the European Hematology Association (EHA) Hybrid Congress being held June 13-16, 2024, in Madrid, Spain, and via livestream.

Editas Medicine to Present Clinical Data from the RUBY and EdiTHAL Trials of Reni-cel at the European Hematology Association 2024 Congress in June

Research includes the first-ever application of AsCas12a in vivo, optimized LNP delivery, and gene editing RNA guide modifications

Editas Medicine Preclinical Data Highlights Advancement of in vivo Gene Editing Medicine Technologies at the American Society of Gene and Cell Therapy Annual Meeting

Editas (EDIT) reports weaker-than-expected first-quarter 2024 results as both earnings and revenues fall shy of estimates. Shares fall.

Editas (EDIT) Q1 Earnings & Revenues Lag Estimates, Stock Down

Even after a slight price target reduction, the analyst feels the biotech's shares could see a major pop. In her view, management has devised the right strategy for developing its investigational products.

1 Wall Street Analyst Thinks Editas Medicine Stock Is Going to $15. Is It a Buy Around $5?

Editas Medicine, Inc. (NASDAQ:EDIT ) Q1 2024 Earnings Conference Call May 8, 2024 8:00 AM ET Company Participants Cristi Barnett - Corporate Communications and IR Gilmore O'Neill - CEO Baisong Mei - CMO Erick Lucera - CFO Linda Burkly - CSO Caren Deardorf - Chief Commercial and Strategy Officer Conference Call Participants Samantha Semenkow - Citi Joon Lee - Truist Securities Mary Kate Davis - Bank of America Jack Allen - Baird Gena Wang - Barclays Brian Cheng - JPMorgan Eric Schmidt - Cantor Fitzgerald Jay Olson - Oppenheimer & Company Yanan Zhu - Wells Fargo Luca Issi - RBC Capital Mani Foroohar - Leerink Partners Operator Good morning, and welcome to the Editas Medicine's First Quarter 2024 Conference Call. All participants are now in a listen-only mode.

Editas Medicine, Inc. (EDIT) Q1 2024 Earnings Call Transcript

Editas Medicine (EDIT) came out with a quarterly loss of $0.76 per share versus the Zacks Consensus Estimate of a loss of $0.63. This compares to loss of $0.71 per share a year ago.

Editas Medicine (EDIT) Reports Q1 Loss, Misses Revenue Estimates

Completed adult cohort enrollment and enrolled multiple patients in the adolescent cohort of the Phase 1/2/3 RUBY clinical trial of reni-cel for severe sickle cell disease

News for Editas Medicine Stock (EDIT)